nach oben

Erschienen in:

01.12.2015

Health-related quality of life in Parkinson’s: impact of ‘off’ time and stated treatment preferences

verfasst von: Cicely Kerr, Emily J. Lloyd, Charlotte E. Kosmas, Helen T. Smith, James A. Cooper, Karissa Johnston, Emma McIntosh, Andrew J. Lloyd

Erschienen in: Quality of Life Research | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of ‘off time’ resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson’s (PwP).

Methods

PwP across UK, France, Spain and Italy completed an online survey to explore: the impact of ‘off time’ on (1) health-related quality of life (HRQL) and (2) on functioning and ability to undertake usual activities; (3) the value of ‘off time’ relative to other factors associated with Parkinson’s through a stated preference discrete choice experiment (SPDCE).

Results

In total, 305 PwP completed the online survey. Overall mean HRQL (utility) score was significantly lower for ‘off time’ (0.37) than for ‘on time’ (0.60). All attributes within the SPDCE were significant predictors of treatment choice, although increased duration of ‘on time’ (per hour per day: odds ratio (OR) = 1.40) and predictability of ‘off time’ to within 30 min (OR = 1.42) were valued most highly.

Conclusions

‘On time’ and predictability of ‘off time’ are highly valued by PwP. Due to substantial diurnal variation of Parkinson’s symptoms, standard patient-reported outcome (PRO) assessments may not adequately capture the impact of ‘off time’ on HRQL and participation in daily activities.

Nur mit Berechtigung zugänglich

Sample excludes 30 pilots, includes those failing the logic and consistency checks.

Weintraub, D., Comella, C. L., & Stacy, H. (2010). Parkinson’s disease—Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. The American Journal of Managed Care, 14, S40–S48.

Müller, T. (2013). Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson’s disease: Focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clinical Neuropharmacology, 36, 84–91.CrossRefPubMed

Antonini, A., Martinez-Martin, P., Chaudhuri, R. K., Merello, M., Hauser, R., Katzenschlager, R., et al. (2011). Wearing-off scales in Parkinson’s disease: Critique and recommendations. Movement Disorders, 26(12), 2169–2175.CrossRefPubMed

Stocchi, F. (2006). The levodopa wearing-off phenomenon in Parkinson’s disease: Pharmacokinetic considerations. Expert Opinion on Pharmacotherapy, 7, 1399–1407.CrossRefPubMed

Hauser, R. A. (2012). IPX066: A novel carbidopa-levodopa extended-release formulation. Expert Review of Neurotherapeutics, 12, 133–140.CrossRefPubMed

Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013). The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacological Reviews, 65, 171–222.CrossRefPubMed

Gomez-Esteban, J. C., Zarranz, J. J., Lezcano, E., Tijero, B., Luna, A., Velasco, F., et al. (2007). Influence of motor symptoms upon the quality of life of patients with Parkinson’s disease. European Neurology, 57, 161–165.CrossRefPubMed

Montel, S., Bonnet, A. M., & Bungener, C. (2009). Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson’s disease. Journal of Geriatric Psychiatry, 22(2), 95–102.CrossRef

Rahman, S., Griffin, H. J., Quinn, N. P., & Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23(10), 1428–1434.CrossRefPubMed

10.

Palmer, C. S., Schmier, J. K., Snyder, E., & Scott, B. (2000). Patient preferences and utilities for ‘off-time’ outcomes in the treatment of Parkinson’s disease. Quality of Life Research, 9(7), 819–827.CrossRefPubMed

11.

Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727–1736.CrossRefPubMedPubMedCentral

12.

Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson’s Disease Questionnaire (PDQ-39): Development and validation of Parkinson’s disease summary index score. Age and Ageing, 26, 353–357.CrossRefPubMed

13.

Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3, 77–101.CrossRef

14.

Fahn, S., & Elton, R. L. (1987). Members of the UPDRS Development Committee. The United Parkinson’s Disease Rating Scale. In S. Fahn, C. D. Marsden, D. B. Caine, & M. Goldstein (Eds.), Recent developments in Parkinson’s disease, Vol 2 (pp. 153-163–293-304). Florham Park: Macmillian Healthcare Information.

15.

McIntosh, E. (2006). Using stated preference discrete choice experiments in cost-benefit analysis: Some considerations. Pharmacoeconomics, 24(9), 855–869.CrossRefPubMed

16.

McIntosh, E., Clarke, P., Frew, E., & Louviere, J. J. (2010). Applied methods of cost-benefit analysis in health care. In A. Gray & A. Briggs (Eds.), Handbooks in health economic evaluation. Oxford: Oxford University Press.

17.

Ryan, M., & Gerard, K. (2003). Using discrete choice experiments to value health care programmes: Current practice and future research reflections. Applied health economics and health policy, 2(1), 55–64.PubMed

18.

Bridges, J. F., Hauber, A. B., Marshall, D., Lloyd, A., Prosser, L. A., Regier, D. A., et al. (2011). Conjoint analysis applications in health—a checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health, 14(4), 403–413.CrossRefPubMed

19.

Petrou, S., & McIntosh, E. (2009). Using discrete choice experiments to elicit women’s preferences for alternative forms of miscarriage management. Value in Health, 12(4), 551–559.CrossRefPubMed

20.

Ossa, D. F., Briggs, A., McIntosh, E., Cowell, W., Littlewood, T., & Sculpher, M. (2007). Using direct utility elicitation and discrete choice studies to assess the impact of chemotherapy-related anaemia on the health-related quality-of-life of cancer, and the value of rHu-EPO treatment. Pharmacoeconomics, 25(3), 223–237.CrossRefPubMed

21.

Lloyd, A., McIntosh, E., Rabe, K., & Williams, A. (2007). Patient preferences for asthma therapy: A discrete choice experiment. Primary Care Respiratory Journal, 16(4), 241–248.CrossRefPubMed

22.

Kleinman, L., McIntosh, E., Ryan, M., Schmier, J., Crawley, J., Locke, G. R., & de Lissovoy, G. (2002). Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Archives of Internal Medicine, 162, 1361–1366.CrossRefPubMed

23.

Ryan, M., McIntosh, E., Dean, T., & Old, P. (2000). Trade offs between location and waiting times in the provision of health care: The case of elective surgery on the Isle of Wight. Journal of Public Health Medicine, 22(2), 202–210.CrossRefPubMed

24.

Hattori, N., Fujimoto, K., Kondo, T., Murata, M., & Stacy, M. (2012). Patient perspectives on Parkinson’s disease therapy in Japan and the United States: Results of two patient surveys. Patient Related Outcomes Measures, 3, 31–38.CrossRef

25.

Burgess, L., & Street, D. J. (2005). Optimal designs for choice experiments with asymmetric attributes. Journal of Statistical Physics, 134(1), 288–301.

26.

van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 15(5), 708–715.CrossRefPubMed

27.

Lancsar, E., & Louviere, J. (2008). Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics, 26, 661–677.CrossRefPubMed

28.

Johnson, F. R., Hauber, B., Ozdemir, S., Siegel, C. A., Hass, S., & Sands, B. E. (2010). Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. Journal of Managed Care Pharmacy, 16(8), 616–628.CrossRefPubMed

29.

Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14(6), 1523–1532.CrossRefPubMed

30.

Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 70.CrossRefPubMedPubMedCentral

31.

Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005). Impact of the motor complications of Parkinson’s disease on the quality of life. Movement Disorders, 20(2), 224–230.CrossRefPubMed

32.

Haahr, A., Kirkevold, M., Hall, E. O., & Østergaard, K. (2011). Living with advanced Parkinson’s disease: A constant struggle with unpredictability. Journal of Advanced Nursing, 67(2), 408–417.CrossRefPubMed

33.

Marras, C., Lang, A., Krahn, M., Tomlinson, G., & Naglie, G. (2004). Quality of life in early Parkinson’s disease: Impact of dyskinesias and motor fluctuations. Movement Disorders, 19(1), 22–28.CrossRefPubMed

34.

Gómez-Esteban, J. C., Tijero, B., Somme, J., Ciordia, R., Berganzo, K., Rouco, I., et al. (2011). Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. Journal of Neurology, 258(3), 494–499.CrossRefPubMed

35.

Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Herlofson, K., & Alves, G. (2008). Predictors and course of health-related quality of life in Parkinson’s disease. Movement Disorders, 23(10), 1420–1427.CrossRefPubMed

36.

Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129–2170.CrossRefPubMed

37.

Morley, D., Dummett, S., Kelly, L., Dawson, J., Fitzpatrick, R., & Jenkinson, C. (2013). Development of the Oxford Participation & Activities Questionnaire: Semi structured interviews with potential users. Journal of the Neurological Sciences, 333, e651.CrossRef

Titel: Health-related quality of life in Parkinson’s: impact of ‘off’ time and stated treatment preferences
verfasst von: Cicely Kerr
Emily J. Lloyd
Charlotte E. Kosmas
Helen T. Smith
James A. Cooper
Karissa Johnston
Emma McIntosh
Andrew J. Lloyd
Publikationsdatum: 01.12.2015
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 6/2016
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-015-1187-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Health-related quality of life in Parkinson’s: impact of ‘off’ time and stated treatment preferences

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Quality of life across medical conditions and psychological factors: implications for population health management

Structural and construct validity of the Leeds Multiple Sclerosis Quality of Life scale

Obesity, metabolic abnormality, and health-related quality of life by gender: a cross-sectional study in Korean adults

The Guttman errors as a tool for response shift detection at subgroup and item levels

Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice

Cardiff cardiac ablation patient-reported outcome measure (C-CAP): validation of a new questionnaire set for patients undergoing catheter ablation for cardiac arrhythmias in the UK